Parkinson's disease trials recruiting in Tennessee

All Parkinson's disease trials nationally

Cities in Tennessee

Recruiting trials in Tennessee

• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Tennessee: Nashville
• A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
  NCT06285643 · Phase: Phase 2 · Ages: 45 Years to 75 Years · Sex: All (male and female) · Tennessee: Nashville
• A Study of Buntanetap in Participants With PD
  NCT07284784 · Phase: Phase 2, Phase 3 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Tennessee: Cordova, Memphis
• A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
  NCT07432958 · Phase: Phase 2 · Ages: 30 Years to 80 Years · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
  NCT07174310 · Phase: Phase 3 · Ages: 50 Years to 85 Years · Sex: All (male and female) · Tennessee: Memphis, Nashville
• A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
  NCT07804615 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Tennessee: Memphis
• A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
  NCT06944522 · Phase: Phase 3 · Ages: 45 Years to 75 Years · Sex: All (male and female) · Tennessee: Nashville
• Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
  NCT07428447 · Phase: Not specified · Ages: 50 Years to 85 Years · Sex: All (male and female) · Tennessee: Memphis
• Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment
  NCT04715984 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Neurophysiology of Reward Signaling in Parkinson's Disease
  NCT07409207 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Parkinson's Foundation PD GENEration Genetic Registry
  NCT04994015 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Physiological Brain Atlas Development
  NCT00575081 · Phase: Not specified · Ages: 6 Years to 90 Years · Sex: All (male and female) · Tennessee: Nashville
• Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
  NCT04373317 · Phase: Phase 4 · Ages: 40 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
  NCT02071134 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Use of CereGate Therapy for Freezing of Gait in PD
  NCT05292794 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years to 80 Years · Sex: All (male and female) · Tennessee: Nashville